drugset / Trial / NCT04911062

HTX-011 in Spinal Surgery

NCT04911062

Phase 2 Completed 32 enrolled Heron Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.

Timeline

Start
2022-04-07
Primary completion
2022-07-29
Completion
2022-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 100 mg Other
Subject Bupivacaine Other / unclassified 200 mg Other
Subject Meloxicam Small molecule 6 mg Other

Indications

No indication recorded.